Cemdomespib
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2017 (NCT02666963)
Timeline
Indications
Studied for
Mechanism of action
HSP90AB2P inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CO[C@@H]1[C@@H](O)[C@@H](O)[C@H](Oc2ccc(CCNC(C)=O)c(-c3cccc(F)c3)c2)OC1(C)C- Mol. weight
- 447.5 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2159227 ↗
Also known as
- rta 901
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05895552 | Phase 2 | Aug 21, 2023 | Biogen |
| NCT02666963 | Phase 1 | Jan 1, 2017 | Reata Pharmaceuticals, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biogen | For profit | 1 | 1 | 1 | 2023 |
| Reata Pharmaceuticals, Inc. | For profit | 1 | 1 | 1 | 2017 |
2 organizations
Page 1 / 1